Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and why this meeting is so important in this space. The combination of ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

The phase 2 study – reported at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado – looked at the combination of MSD’s experimental long-acting reverse ...

based on this latest study presented at the Conference of Retroviruses and Opportunistic Infections. (The study has not yet been published in a peer-reviewed journal.) Researchers studied more ...

During the “Hot Topic: Menopause and HIV” mini symposia at the 2025 Conference on Retroviruses and Opportunistic Infections, Bridgette J. Picou, LVN, ACLPN, stakeholder liaison, The Well ...

This study that evaluates an annual injection of a pre-exposure prophylaxis medication for HIV has been published in The Lancet and presented simultaneously at the Conference on Retroviruses and ...

SAN FRANCISCO — During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV survivor, addressed conference attendees and discussed ...

researchers said at the Conference on Retroviruses and Opportunistic Infections.